# A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Source: https://onco.cc/trials/seacraft-2/  
OnCo record `seacraft-2` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial testing Naporafenib in melanoma, active and no longer recruiting.

## Summary

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) is a phase 3 interventional study registered as NCT06346067, led by Erasca, and active but no longer recruiting on the registry. Official title: A Randomised, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]. Planned enrolment is 78 participants (actual). The study started in 2024-04-29 and primary completion is expected in 2028-04. No results have been posted on ClinicalTrials.gov.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-11
- Also known as: SEACRAFT-2
- Tags: ctgov-ingest
- Registry id: NCT06346067
- Phase: 3
- Setting: A Randomized, Open-label Phase III Study in Patients With Previously Treated Unresectable or Metastatic NRAS Mutant Cutaneous Melanoma Comparing the Combination of Naporafenib + Trametinib to Physician's Choice of Therapy (Dacarbazine, Temozolomide or Trametinib Monotherapy) With a Dose Optimization lead-in [SEACRAFT-2]
- Sponsor: Erasca
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT06346067: https://clinicaltrials.gov/study/NCT06346067

## Connected records

- cancers: [Acral melanoma](https://onco.cc/cancers/acral-melanoma/), [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/), [Mucosal melanoma](https://onco.cc/cancers/mucosal-melanoma/)
- drugs: [Naporafenib](https://onco.cc/drugs/naporafenib/)
- companies: [Erasca](https://onco.cc/companies/erasca/)

---
JSON: https://onco.cc/api/v1/entities/seacraft-2.json